SG25195G - Hybrid interferons - Google Patents
Hybrid interferonsInfo
- Publication number
- SG25195G SG25195G SG25195A SG25195A SG25195G SG 25195 G SG25195 G SG 25195G SG 25195 A SG25195 A SG 25195A SG 25195 A SG25195 A SG 25195A SG 25195 G SG25195 G SG 25195G
- Authority
- SG
- Singapore
- Prior art keywords
- interferons
- hybrid interferons
- novel hybrid
- hybrid
- interferon
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/249—Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/56—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S930/00—Peptide or protein sequence
- Y10S930/01—Peptide or protein sequence
- Y10S930/14—Lymphokine; related peptides
- Y10S930/142—Interferon
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Plant Pathology (AREA)
- Communicable Diseases (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Saccharide Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SG25195A SG25195G (en) | 1985-06-11 | 1995-02-16 | Hybrid interferons |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB858514725A GB8514725D0 (en) | 1985-06-11 | 1985-06-11 | Hybrid polypeptide |
GB858514723A GB8514723D0 (en) | 1985-06-11 | 1985-06-11 | Hybrid alpha-interferon |
GB858514722A GB8514722D0 (en) | 1985-06-11 | 1985-06-11 | Hybrid interferon |
GB858514726A GB8514726D0 (en) | 1985-06-11 | 1985-06-11 | Hybrid polypeptides |
GB858514724A GB8514724D0 (en) | 1985-06-11 | 1985-06-11 | Hybrid alpha-interferon |
SG25195A SG25195G (en) | 1985-06-11 | 1995-02-16 | Hybrid interferons |
Publications (1)
Publication Number | Publication Date |
---|---|
SG25195G true SG25195G (en) | 1995-08-18 |
Family
ID=27516593
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG25195A SG25195G (en) | 1985-06-11 | 1995-02-16 | Hybrid interferons |
Country Status (20)
Country | Link |
---|---|
US (2) | US4885166A (da) |
EP (1) | EP0205404B1 (da) |
JP (2) | JPH0655759B2 (da) |
KR (1) | KR920002267B1 (da) |
AT (1) | ATE78262T1 (da) |
AU (1) | AU598196B2 (da) |
CA (1) | CA1285507C (da) |
CY (1) | CY1842A (da) |
DE (1) | DE3685996T2 (da) |
DK (1) | DK168794B1 (da) |
FI (1) | FI90983C (da) |
GR (1) | GR861497B (da) |
HK (1) | HK99895A (da) |
HU (1) | HU203255B (da) |
IE (1) | IE57865B1 (da) |
IL (1) | IL79085A (da) |
NO (1) | NO175602C (da) |
NZ (1) | NZ216485A (da) |
PT (1) | PT82736B (da) |
SG (1) | SG25195G (da) |
Families Citing this family (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5359035A (en) * | 1985-12-21 | 1994-10-25 | Hoechst Aktiengesellschaft | Bifunctional proteins including interleukin-2 (IL-2) and granuloctyte macrophage colony stimulating factor (GM-CSF) |
DE3607835A1 (de) * | 1986-03-10 | 1987-09-24 | Boehringer Ingelheim Int | Hybridinterferone, deren verwendung als arzneimittel und als zwischenprodukte zur herstellung von antikoerpern und deren verwendung sowie verfahren zu ihrer herstellung |
GB8803365D0 (en) * | 1988-02-13 | 1988-03-16 | Ciba Geigy Ag | Antiviral combination |
EP0331635A3 (en) * | 1988-02-29 | 1990-02-28 | The Board of Regents of the University of Texas System | Preparations for treating bladder cancer |
US5594107A (en) * | 1990-08-22 | 1997-01-14 | University Of Saskatchewan | Chimeric protein comprising an RTX-family cytotoxin and interferon-2 or interferon |
US5273889A (en) * | 1990-08-22 | 1993-12-28 | University Of Saskatchewan | Gamma-iterferon-leukotoxin gene fusions and uses thereof |
AU651152B2 (en) * | 1990-08-29 | 1994-07-14 | Genetics Institute, Llc | Multidomain hematopoiesis stimulators |
US5372808A (en) † | 1990-10-17 | 1994-12-13 | Amgen Inc. | Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect |
ATE157703T1 (de) * | 1991-12-16 | 1997-09-15 | Ciba Geigy Ag | Endoplasmatisches retikulum-ständige rekombinante dibasische endoprotease und deren verwendungen |
US5676942A (en) * | 1992-02-10 | 1997-10-14 | Interferon Sciences, Inc. | Composition containing human alpha interferon species proteins and method for use thereof |
DE69323131T2 (de) * | 1992-03-10 | 1999-09-16 | La Jolla Cancer Research Foundation, La Jolla | Rekombinierte alkalische phosphatase aus kälberdarm |
TW218846B (da) * | 1992-04-07 | 1994-01-11 | Ciba Geigy | |
JPH078215A (ja) * | 1993-04-30 | 1995-01-13 | Kawasaki Steel Corp | ドコサヘキサエン酸含有海洋性微細藻類食品素材およびその製造方法 |
TW249202B (da) * | 1993-08-13 | 1995-06-11 | Ciba Gerigy Corp | |
WO1996024678A1 (en) | 1995-02-09 | 1996-08-15 | Novartis Ag | Process for the production of proteins |
TW442492B (en) * | 1995-07-26 | 2001-06-23 | Novartis Ag | Process for the enrichment of interferon |
US6685933B1 (en) * | 1998-07-28 | 2004-02-03 | The United States Of America As Represented By The Department Of Health And Human Services | Interferon α hybrids |
LT2599503T (lt) | 1998-10-16 | 2017-06-26 | Biogen Ma Inc. | Interferono beta-1a polimero konjugatai ir jų panaudojimas |
US6514729B1 (en) * | 1999-05-12 | 2003-02-04 | Xencor, Inc. | Recombinant interferon-beta muteins |
AU2587002A (en) * | 2000-11-03 | 2002-05-15 | Biomedicines Inc | Method for short-term and long-term drug dosimetry |
US7087726B2 (en) * | 2001-02-22 | 2006-08-08 | Genentech, Inc. | Anti-interferon-α antibodies |
FR2821625B1 (fr) * | 2001-03-01 | 2003-05-16 | Genodyssee | Nouveaux polynucleotides comportant un polymorphisme de type snp fonctionnel dans la sequence nucleotidique du gene ifn-alpha-2 ainsi que de nouveaux polypeptides codes par ces polynucleotides et leurs utilisations therapeutiques |
FR2823220B1 (fr) * | 2001-04-04 | 2003-12-12 | Genodyssee | Nouveaux polynucleotides et polypeptides de l'erythropoietine (epo) |
EP1536839B1 (en) * | 2001-11-09 | 2010-09-15 | Intarcia Therapeutics, Inc | Combination therapy comprising omega-interferon for treating infection with hepatitis c virus or yellow fever virus |
US20040175359A1 (en) * | 2002-11-12 | 2004-09-09 | Desjarlais John Rudolph | Novel proteins with antiviral, antineoplastic, and/or immunomodulatory activity |
AU2003297285A1 (en) * | 2002-11-18 | 2004-06-15 | Maxygen, Inc. | Interferon-alpha polypeptides and conjugates |
US7314613B2 (en) | 2002-11-18 | 2008-01-01 | Maxygen, Inc. | Interferon-alpha polypeptides and conjugates |
US7731947B2 (en) | 2003-11-17 | 2010-06-08 | Intarcia Therapeutics, Inc. | Composition and dosage form comprising an interferon particle formulation and suspending vehicle |
TW200611910A (en) * | 2004-05-19 | 2006-04-16 | Maxygen Inc | Interferon-alpha polypeptides and conjugates |
JP2008509889A (ja) * | 2004-06-30 | 2008-04-03 | イージェン コーポレーション | ペグ化インターフェロンα−1b |
US11246913B2 (en) | 2005-02-03 | 2022-02-15 | Intarcia Therapeutics, Inc. | Suspension formulation comprising an insulinotropic peptide |
WO2006083761A2 (en) | 2005-02-03 | 2006-08-10 | Alza Corporation | Solvent/polymer solutions as suspension vehicles |
CA2607651A1 (en) | 2005-05-18 | 2007-04-19 | Maxygen, Inc. | Evolved interferon-alpha polypeptides |
AU2007266475B2 (en) | 2006-05-30 | 2009-12-03 | Intarcia Therapeutics, Inc. | Two-piece, internal-channel osmotic delivery system flow modulator |
EP2041259B1 (en) | 2006-07-14 | 2015-10-14 | DPx Holdings B.V. | Improved process for the culturing of cells |
DK2049081T3 (da) | 2006-08-09 | 2013-02-25 | Intarcia Therapeutics Inc | Osmotiske leveringssystemer og stempelarrangementer |
BRPI0720035A2 (pt) | 2006-12-06 | 2019-05-07 | Medimmune, Llc | métodos para tratar um paciente tendo uma doença ou distúrbio, para tratar um paciente com doença autoimune, para neutralizar um perfil de expressão do marcador pd indutível por ifn do tipo 1 ou ifnalfa em um paciente, para monitorar ou prognosticar progressão de doença autoimune de um paciente, para monitorar a progressão da doença de um paciente que recebe o tratamento com um agente terapêutico que liga-se a e modula a atividade de ifnalfa, para identificar um paciente como um candidato para um agente terapêutico que liga-se a e modula a atividade de ifnalfa, para diagnosticar um paciente como tendo um distùrbio associado com níveis aumentados de ifnalfa, para identificar um terapêutico candidato para o tratamento de distùrbios mediados por ifnalfa e para detectar atividade de ifn em uma amostra, conjunto de sondas, e, kit |
PT2157967E (pt) | 2007-04-23 | 2013-04-03 | Intarcia Therapeutics Inc | Formulações de suspensões de péptidos insulinotrópicos e suas utilizações |
NZ580686A (en) * | 2007-05-02 | 2012-11-30 | Ambrx Inc | Modified interferon beta polypeptides and their uses |
JP5411129B2 (ja) | 2007-05-03 | 2014-02-12 | メディミューン,エルエルシー | インターフェロンα誘導性薬力学的マーカー |
US7625555B2 (en) | 2007-06-18 | 2009-12-01 | Novagen Holding Corporation | Recombinant human interferon-like proteins |
WO2009061818A1 (en) | 2007-11-05 | 2009-05-14 | Medimmune, Llc | Methods of treating scleroderma |
ES2529593T3 (es) | 2008-02-08 | 2015-02-23 | Medimmune, Llc | Marcadores de enfermedades y usos de los mismos |
DK2240155T3 (da) | 2008-02-13 | 2012-09-17 | Intarcia Therapeutics Inc | Indretninger, formuleringer og fremgangsmåder til levering af flere gavnlige midler |
KR20120101340A (ko) | 2009-09-03 | 2012-09-13 | 메디뮨 엘엘씨 | 1형 인터페론 진단 |
KR102148624B1 (ko) | 2009-09-28 | 2020-08-26 | 인타르시아 세라퓨틱스 인코포레이티드 | 실질 항정상태 약물 전달의 신속 확립 및/또는 종결 |
US20120208755A1 (en) | 2011-02-16 | 2012-08-16 | Intarcia Therapeutics, Inc. | Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers |
KR102050339B1 (ko) | 2011-03-15 | 2019-11-29 | 바이오젠 엠에이 인코포레이티드 | 빠른 적정 단계식 증가 투여 요법을 이용한 인터페론의 근육내 투여와 관련된 독감 유사 증상의 감소 방법 |
US8729236B2 (en) * | 2011-05-23 | 2014-05-20 | Hal S. Padgett | Selection and characterization of novel plant-derived recombinant human interferons with broad spectrum activity |
US9889085B1 (en) | 2014-09-30 | 2018-02-13 | Intarcia Therapeutics, Inc. | Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c |
KR20240042548A (ko) | 2015-06-03 | 2024-04-02 | 인타르시아 세라퓨틱스 인코포레이티드 | 임플란트 배치 및 제거 시스템들 |
CN109310743A (zh) | 2016-05-16 | 2019-02-05 | 因塔西亚制药公司 | 胰高血糖素受体选择性多肽及其使用方法 |
USD840030S1 (en) | 2016-06-02 | 2019-02-05 | Intarcia Therapeutics, Inc. | Implant placement guide |
USD860451S1 (en) | 2016-06-02 | 2019-09-17 | Intarcia Therapeutics, Inc. | Implant removal tool |
KR20190104039A (ko) | 2017-01-03 | 2019-09-05 | 인타르시아 세라퓨틱스 인코포레이티드 | Glp-1 수용체 효능제의 연속적인 투여 및 약물의 동시-투여를 포함하는 방법 |
JP7522749B2 (ja) | 2019-02-15 | 2024-07-25 | アストラゼネカ・アクチエボラーグ | I型インターフェロン媒介性障害 |
KR102594862B1 (ko) * | 2023-06-14 | 2023-10-27 | (주) 신성하이스킬 | 화재방지 파쇄 시스템 |
KR102570958B1 (ko) * | 2023-06-14 | 2023-08-25 | (주) 신성하이스킬 | 화재방지 4축 파쇄장치 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NO164037C (no) * | 1980-01-08 | 1990-08-22 | Biogen Inc | Fremgangsmaate ved fremstilling av et polypeptid av interferon alfa (ifnalfa)-type. |
US4414150A (en) * | 1980-11-10 | 1983-11-08 | Genentech, Inc. | Hybrid human leukocyte interferons |
US4456748A (en) * | 1981-02-23 | 1984-06-26 | Genentech, Inc. | Hybrid human leukocyte interferons |
ES506955A0 (es) * | 1980-11-10 | 1983-02-01 | Genentech Inc | Un procedimiento para producir un polipeptido antiviral. |
GB2108510B (en) * | 1981-10-03 | 1984-12-12 | Ciba Geigy Ag | Dnas, recombinant dnas, hosts containing them, polypeptides and processes for the production thereof |
WO1983002461A1 (en) * | 1982-01-19 | 1983-07-21 | Cetus Corp | Multiclass hybrid interferons |
GB8315980D0 (en) * | 1983-06-10 | 1983-07-13 | Biogen Nv | Producing hybrid dna sequences |
GB8317880D0 (en) * | 1983-07-01 | 1983-08-03 | Searle & Co | Structure and synthesis of interferons |
EP0146903A3 (en) * | 1983-12-19 | 1987-07-22 | Schering Corporation | Production of a vector encoding a novel hybrid interferon species |
GB8412564D0 (en) * | 1984-05-17 | 1984-06-20 | Searle & Co | Structure and properties |
EP0173935A1 (en) * | 1984-08-31 | 1986-03-12 | University Patents, Inc. | Hybrid lymphoblastoid-leukocyte human interferons |
US4716217A (en) * | 1984-08-31 | 1987-12-29 | University Patents, Inc. | Hybrid lymphoblastoid-leukocyte human interferons |
-
1986
- 1986-06-05 EP EP86810243A patent/EP0205404B1/en not_active Expired - Lifetime
- 1986-06-05 AT AT86810243T patent/ATE78262T1/de not_active IP Right Cessation
- 1986-06-05 US US06/871,059 patent/US4885166A/en not_active Expired - Lifetime
- 1986-06-05 DE DE8686810243T patent/DE3685996T2/de not_active Expired - Lifetime
- 1986-06-09 CA CA000511107A patent/CA1285507C/en not_active Expired - Lifetime
- 1986-06-09 FI FI862461A patent/FI90983C/fi not_active IP Right Cessation
- 1986-06-09 GR GR861497A patent/GR861497B/el unknown
- 1986-06-09 PT PT82736A patent/PT82736B/pt unknown
- 1986-06-10 JP JP61132895A patent/JPH0655759B2/ja not_active Expired - Lifetime
- 1986-06-10 AU AU58499/86A patent/AU598196B2/en not_active Expired
- 1986-06-10 NO NO862313A patent/NO175602C/no not_active IP Right Cessation
- 1986-06-10 HU HU862457A patent/HU203255B/hu unknown
- 1986-06-10 KR KR1019860004580A patent/KR920002267B1/ko not_active IP Right Cessation
- 1986-06-10 IE IE1542/86A patent/IE57865B1/en not_active IP Right Cessation
- 1986-06-10 IL IL79085A patent/IL79085A/xx not_active IP Right Cessation
- 1986-06-10 DK DK272986A patent/DK168794B1/da not_active IP Right Cessation
- 1986-06-10 NZ NZ216485A patent/NZ216485A/en unknown
-
1989
- 1989-07-18 US US07/381,444 patent/US5071761A/en not_active Expired - Lifetime
-
1992
- 1992-10-14 JP JP4276015A patent/JPH0736757B2/ja not_active Expired - Lifetime
-
1995
- 1995-02-16 SG SG25195A patent/SG25195G/en unknown
- 1995-06-22 HK HK99895A patent/HK99895A/xx not_active IP Right Cessation
-
1996
- 1996-03-08 CY CY184296A patent/CY1842A/xx unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0205404A3 (en) | Hybrid interferons | |
DE3583521D1 (de) | Antivirale verbindungen. | |
AU2964489A (en) | Dna sequences, recombinant dna molecules and processes for producing human immune interferon-like polypeptides | |
ES8500996A1 (es) | Meotod de producir un polipeptido. | |
EP0263072A3 (en) | Novel lymphokine related peptides | |
IE822385L (en) | Recombinant dna's coding for interferon polypeptides | |
FI850275L (fi) | Nya 6-susbtituerade furo-(3,4-c) -pyridinderivat. | |
ES8609475A1 (es) | Procedimiento para preparar peptidos de interferon | |
NZ228105A (en) | Antihypertensive hyperimmune milk, its production and medicaments therefrom | |
EP0315637A4 (en) | POLYPEPTIDES USEFUL IN THE DIAGNOSIS OF MYCOPLASMA INFECTIONS IN PIGS, AND RECOMBINANT DNA METHODS FOR THEIR MANUFACTURE. | |
AU598460B2 (en) | Process preparing and purifying interferon | |
ES8404373A1 (es) | Un procedimiento para obtener compuestos de ribofuranosilselenazol-4-carboxamida. | |
AU4970885A (en) | Novel lymphokine, monoclonal antibody specific to the lymphokine, and their production and uses | |
ES2001108A6 (es) | Un procedimiento para la preparacion de un derivado de gem-dihalo-1,8-diamino -4 -aza-octano. | |
EP0276120A3 (en) | Treatment of certain leukemias with a combination of gamma interferon and alpha interferon | |
SU939352A1 (ru) | Двухмассный вибрационный конвейер |